PBRM1 and renal cell carcinoma: Given the findings of Miao et al.6 and Braun et al.9 with respect to PBRM1 LOF mutations and response to ICB in RCC, we analyzed our cohort of ICB-treated metastatic ccRCC patients (n = 189) with more detailed clinical annotations including International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic score (n = 180; Table 2), treatment details and outcomes with therapy, including time-to-treatment failure (TTF).